MELBOURNE, Australia, Aug 24 (Bernama-AsiaNet) --
| * Refund based on AUD$2.8 million in eligible R&D spending used to advance the Company's development programs. * Two nutraceutical products currently being prepared for US launch by end of 2016. Gordagen Pharmaceuticals, a private Australian company developing biopharmaceuticals and nutraceuticals based on the medicinal properties of tocotrienols, is pleased to announce it has received a Research and Development Tax Incentive Refund of AUD$1.3 million for the 2015/2016 financial year. http://mrem.bernama.com/viewsm.php?idm=27384 |
No comments:
Post a Comment